Concepts (110)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Robotic Surgical Procedures | 4 | 2021 | 54 | 1.520 |
Why?
|
| Cryptorchidism | 2 | 2021 | 10 | 1.340 |
Why?
|
| Laparoscopy | 3 | 2021 | 159 | 1.280 |
Why?
|
| Urinary Bladder Diseases | 2 | 2021 | 9 | 1.270 |
Why?
|
| Electric Stimulation Therapy | 2 | 2021 | 58 | 1.230 |
Why?
|
| Orchiopexy | 2 | 2020 | 2 | 1.210 |
Why?
|
| Ureteral Neoplasms | 3 | 2017 | 6 | 1.070 |
Why?
|
| Child | 14 | 2026 | 2354 | 0.990 |
Why?
|
| Adrenalectomy | 2 | 2021 | 13 | 0.840 |
Why?
|
| Child, Preschool | 6 | 2021 | 1213 | 0.710 |
Why?
|
| Neural Tube Defects | 1 | 2021 | 20 | 0.690 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2021 | 5 | 0.690 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2021 | 6 | 0.690 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2021 | 15 | 0.670 |
Why?
|
| Testis | 1 | 2021 | 40 | 0.660 |
Why?
|
| Referral and Consultation | 1 | 2021 | 98 | 0.660 |
Why?
|
| Urogenital Abnormalities | 1 | 2019 | 4 | 0.590 |
Why?
|
| Hydronephrosis | 1 | 2019 | 11 | 0.590 |
Why?
|
| Retrospective Studies | 7 | 2021 | 2659 | 0.580 |
Why?
|
| Spinal Dysraphism | 1 | 2019 | 14 | 0.580 |
Why?
|
| Implantable Neurostimulators | 1 | 2018 | 2 | 0.570 |
Why?
|
| Intestinal Diseases | 1 | 2018 | 11 | 0.570 |
Why?
|
| Adenoma | 2 | 2016 | 61 | 0.530 |
Why?
|
| Enterostomy | 1 | 2017 | 1 | 0.530 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2018 | 38 | 0.520 |
Why?
|
| Constipation | 1 | 2017 | 22 | 0.520 |
Why?
|
| Male | 14 | 2026 | 14120 | 0.510 |
Why?
|
| Surgical Wound Infection | 1 | 2018 | 108 | 0.510 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2017 | 26 | 0.500 |
Why?
|
| Carcinoma in Situ | 1 | 2017 | 46 | 0.500 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2017 | 56 | 0.490 |
Why?
|
| Postoperative Complications | 2 | 2018 | 643 | 0.470 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 103 | 0.470 |
Why?
|
| Humans | 18 | 2026 | 29202 | 0.460 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 540 | 0.390 |
Why?
|
| Adolescent | 5 | 2021 | 3254 | 0.380 |
Why?
|
| Infant, Newborn | 3 | 2021 | 932 | 0.360 |
Why?
|
| Infant | 3 | 2021 | 1066 | 0.350 |
Why?
|
| Female | 7 | 2021 | 15819 | 0.330 |
Why?
|
| Prognosis | 2 | 2021 | 817 | 0.260 |
Why?
|
| Hypospadias | 1 | 2026 | 6 | 0.240 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2026 | 18 | 0.240 |
Why?
|
| Pain Management | 1 | 2026 | 66 | 0.220 |
Why?
|
| Analgesics, Opioid | 1 | 2026 | 121 | 0.220 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2026 | 177 | 0.210 |
Why?
|
| Urodynamics | 1 | 2024 | 5 | 0.210 |
Why?
|
| Delphi Technique | 1 | 2024 | 25 | 0.210 |
Why?
|
| Consensus | 1 | 2024 | 76 | 0.210 |
Why?
|
| Medical Overuse | 1 | 2021 | 3 | 0.170 |
Why?
|
| Datasets as Topic | 1 | 2021 | 22 | 0.170 |
Why?
|
| Diagnostic Errors | 1 | 2021 | 32 | 0.170 |
Why?
|
| Congenital Abnormalities | 1 | 2021 | 19 | 0.170 |
Why?
|
| Quality of Health Care | 1 | 2021 | 84 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 194 | 0.160 |
Why?
|
| Guideline Adherence | 1 | 2021 | 97 | 0.160 |
Why?
|
| Nephrolithiasis | 1 | 2020 | 3 | 0.160 |
Why?
|
| Lymphoma, T-Cell | 1 | 2020 | 8 | 0.160 |
Why?
|
| Ultrasonography | 2 | 2019 | 244 | 0.160 |
Why?
|
| Survival Rate | 1 | 2021 | 433 | 0.160 |
Why?
|
| Kidney Calculi | 1 | 2019 | 6 | 0.160 |
Why?
|
| Lithotripsy | 1 | 2019 | 9 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 250 | 0.150 |
Why?
|
| Prospective Studies | 2 | 2021 | 1287 | 0.150 |
Why?
|
| Acute Kidney Injury | 1 | 2020 | 74 | 0.150 |
Why?
|
| Robotics | 1 | 2019 | 43 | 0.150 |
Why?
|
| Intermittent Urethral Catheterization | 1 | 2019 | 1 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2021 | 845 | 0.150 |
Why?
|
| Cholinergic Antagonists | 1 | 2019 | 4 | 0.150 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2019 | 11 | 0.150 |
Why?
|
| Fluoroscopy | 1 | 2019 | 36 | 0.140 |
Why?
|
| Lumbosacral Plexus | 1 | 2018 | 7 | 0.140 |
Why?
|
| Prosthesis Failure | 1 | 2018 | 23 | 0.140 |
Why?
|
| Remission Induction | 1 | 2018 | 58 | 0.140 |
Why?
|
| Device Removal | 1 | 2018 | 30 | 0.140 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 47 | 0.140 |
Why?
|
| Urinary Bladder | 1 | 2019 | 119 | 0.140 |
Why?
|
| Intraoperative Period | 1 | 2018 | 21 | 0.140 |
Why?
|
| Treatment Outcome | 2 | 2021 | 2442 | 0.140 |
Why?
|
| Survival Analysis | 1 | 2018 | 288 | 0.130 |
Why?
|
| Oklahoma | 1 | 2021 | 1063 | 0.130 |
Why?
|
| Enema | 1 | 2017 | 7 | 0.130 |
Why?
|
| Preoperative Period | 1 | 2017 | 15 | 0.130 |
Why?
|
| Constriction, Pathologic | 1 | 2017 | 36 | 0.130 |
Why?
|
| Quality of Life | 1 | 2021 | 523 | 0.130 |
Why?
|
| Keratins | 1 | 2017 | 10 | 0.130 |
Why?
|
| Adult | 2 | 2021 | 8125 | 0.130 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 126 | 0.120 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 1033 | 0.120 |
Why?
|
| Ureter | 1 | 2016 | 8 | 0.120 |
Why?
|
| Incidence | 1 | 2018 | 580 | 0.120 |
Why?
|
| Ureteral Obstruction | 1 | 2016 | 13 | 0.120 |
Why?
|
| Ileum | 1 | 2016 | 26 | 0.120 |
Why?
|
| Biopsy | 1 | 2015 | 213 | 0.100 |
Why?
|
| Risk Factors | 1 | 2017 | 2144 | 0.090 |
Why?
|
| United States | 1 | 2018 | 2269 | 0.090 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 304 | 0.090 |
Why?
|
| Surveys and Questionnaires | 2 | 2026 | 1021 | 0.080 |
Why?
|
| Young Adult | 1 | 2017 | 2875 | 0.080 |
Why?
|
| Aged | 2 | 2017 | 5647 | 0.080 |
Why?
|
| Middle Aged | 2 | 2017 | 7493 | 0.070 |
Why?
|
| Urologists | 1 | 2026 | 8 | 0.060 |
Why?
|
| Urology | 1 | 2024 | 30 | 0.050 |
Why?
|
| Pediatrics | 1 | 2024 | 117 | 0.050 |
Why?
|
| Ureteroscopy | 1 | 2019 | 5 | 0.040 |
Why?
|
| Urologic Surgical Procedures | 1 | 2016 | 23 | 0.030 |
Why?
|
| Digital Rectal Examination | 1 | 2015 | 3 | 0.030 |
Why?
|
| Image-Guided Biopsy | 1 | 2015 | 20 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 1 | 2015 | 54 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 741 | 0.020 |
Why?
|
| Registries | 1 | 2015 | 399 | 0.020 |
Why?
|